Business Context and Reporting Period
Filing identity: The submitted filing is for EyeGate Pharmaceuticals, Inc., not Kiora Pharmaceuticals, Inc. It is a Form 10-K for the fiscal year ended December 31, 2015, filed March 30, 2016.
EyeGate was a clinical-stage ophthalmic specialty pharmaceutical company developing EGP-437, a dexamethasone phosphate formulation delivered through the proprietary EyeGate II iontophoresis system. The company had no approved or commercialized products and operated in one business and geographic segment.
Key Financial Metrics
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | Pre-revenue |
| Research and development expense | $2.72 million | $0.53 million | +$2.19 million |
| General and administrative expense | $3.96 million | $1.93 million | +$2.03 million |
| Total operating expenses | $6.68 million | $2.46 million | +$4.22 million |
| Net loss | $8.39 million | $1.55 million | +$6.84 million loss |
| Net loss attributable to common stockholders | $16.62 million | $1.77 million | +$14.84 million loss |
| Net loss per share | $2.70 | $9.20 | Improved due to share-count expansion |
| Cash used in operating activities | $4.46 million | $0.95 million | +$3.51 million use |
| Cash and cash equivalents at year-end | $8.39 million | $0.17 million | +$8.23 million |
| Accumulated deficit | $65.26 million | $56.86 million | +$8.39 million |
Gross margin and operating margin are not meaningful because the company reported no product revenue. Interest expense was $1.93 million, including non-cash charges related to debt conversion and debt discount amortization. Stock-based compensation was $1.22 million.
At December 31, 2015, total assets were $9.51 million, current assets were $9.45 million, and current liabilities were $3.42 million. Convertible notes, preferred stock, non-controlling interests, and the warrant liability were eliminated or converted in connection with the 2015 IPO. The company reported no material off-balance-sheet arrangements.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased primarily because of Phase 3 uveitis and macular edema clinical activities.
- General and administrative expense increased due to higher personnel costs and expenses associated with the company’s public offerings.
- Other expense changed from $0.91 million of net other income in 2014 to $1.71 million of net other expense in 2015, primarily because of higher interest expense and lower warrant-liability gains.
- The company completed an IPO in February 2015, receiving approximately $2.72 million of net proceeds, and a follow-on offering in August 2015, receiving approximately $8.75 million of net proceeds.
- All outstanding preferred stock and shareholder notes converted into common stock in connection with the IPO. The conversion generated an $8.22 million deemed dividend and a $1.66 million non-cash beneficial-conversion interest charge.
- In July 2015, Valeant received exclusive worldwide commercial and manufacturing rights to EGP-437 and the EyeGate II system for uveitis. EyeGate received a $1.0 million upfront payment, recognized as deferred revenue and licensing-related receivable items, and became eligible for up to $32.5 million of development and commercial milestones plus royalties.
Outlook, Commentary, Risks, and Unusual Items
- Management expected continued significant operating losses and stated that the company would require additional financing through equity, debt, grants, or collaborations.
- Year-end cash was expected to fund planned operations for approximately 12 to 15 months. The auditors and management disclosed substantial doubt about the company’s ability to continue as a going concern.
- The company planned a confirmatory Phase 3 anterior uveitis trial, with top-line data expected in the first quarter of 2017, subject to enrollment and funding.
- Top-line data from the macular edema extension trial and a post-cataract-surgery trial were expected in the second quarter of 2016.
- The prior Phase 3 uveitis trial showed a response rate comparable to prednisolone acetate but fell just outside the prespecified non-inferiority margin and was not statistically significant on the primary endpoint. A successful confirmatory trial remained necessary for a potential NDA filing.
- The company also planned a separate safety trial assessing corneal endothelial cell counts over six months, expected to involve at least 100 patients.
- Key risks included clinical-trial failure or delay, inability to obtain FDA approval, dependence on third-party manufacturers and clinical research organizations, limited cash resources, dilution from future financings, competition, reimbursement uncertainty, intellectual-property challenges, and possible termination or disputes under the Valeant agreement.
- Internal control over financial reporting was ineffective because of a material weakness involving preparation and review of the income-tax provision and related disclosures.
- Contractual obligations totaled approximately $3.04 million, including operating leases, licensing commitments, and purchase obligations; an additional potential $150,000 in license milestones was excluded because payment dates were unknown.
- After year-end, on March 7, 2016, EyeGate acquired Jade Therapeutics, Inc. for repayment of $300,000 of Jade liabilities, up to 765,728 EyeGate shares, and a contingent cash earn-out of up to $2.16 million upon FDA approval of a Jade product.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is EyeGate Pharmaceuticals, not Kiora Pharmaceuticals.
- Review the audited financial statements and going-concern disclosure concerning the company’s limited cash runway and need for additional capital.
- Verify the accounting treatment and timing of the $1.0 million Valeant upfront payment, deferred revenue, receivable, milestone rights, and royalty terms.
- Assess the results and regulatory implications of the prior uveitis Phase 3 trial, particularly the failure to meet the prespecified non-inferiority margin.
- Track funding requirements, potential equity dilution, warrant overhang, and the company’s ability to finance planned Phase 3 and safety trials.
- Evaluate remediation of the material weakness in income-tax controls.
- Review the terms, share issuance, contingent consideration, and subsequent accounting for the Jade Therapeutics acquisition.